Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:02 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 2,082 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Label Extension Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke

NCT01428310
View directory record Official record
Conditions
Tobacco Use Disorder, Tobacco Dependence, Smoking
Interventions
Anatabloc(TM), CigRx(R)
Dietary Supplement
Lead sponsor
Rock Creek Pharmaceuticals, Inc.
Industry
Eligibility
23 Years to 72 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Martinsburg, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 1 Interventional

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

NCT01677780
View directory record Official record
Conditions
Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute
Interventions
RO5045337
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Santa Monica, California • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Nov 1, 2026, 5:02 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

NCT05095727
View directory record Official record
Conditions
Glycogen Storage Disease
Interventions
mRNA-3745
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Farmington, Connecticut • Boston, Massachusetts • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 4 Interventional Results available

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

NCT03497689
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Fresno, California • Torrance, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 4 Interventional Results available

Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain

NCT01207596
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Hydromorphone
Drug
Lead sponsor
International Clinical Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

NCT02969369
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
SEP-363856, Placebo capsule
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 105 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Fresno, California • Los Angeles, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 2 Interventional

Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma

NCT00663429
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Atiprimod
Drug
Lead sponsor
Callisto Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Little Rock, Arkansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Nov 1, 2026, 5:02 PM EST
Terminated Phase 2 Interventional Results available

Study in Subjects With Light Chain (AL) Amyloidosis

NCT03154047
View directory record Official record
Conditions
AL Amyloidosis
Interventions
NEOD001
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Duarte, California • Denver, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Nov 1, 2026, 5:02 PM EST
Active, not recruiting Phase 3 Interventional

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

NCT04991116
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
TILD sub-cutaneous (SC) injection
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
41
States / cities
Dothan, Alabama • Gilbert, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

NCT01235338
View directory record Official record
Conditions
Healthy
Interventions
LDX + Venlafaxine XR, Venlafaxine XR + LDX
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Nov 1, 2026, 5:02 PM EST
Terminated Phase 2 Interventional Results available

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

NCT00143247
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exubera® (inhaled insulin)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
12
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Nov 1, 2026, 5:02 PM EST
Terminated Phase 4 Interventional Results available

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

NCT02680847
View directory record Official record
Conditions
Moderate-severe Pain
Interventions
ALO-02
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Lancaster, California • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Nov 1, 2026, 5:02 PM EST
Recruiting Phase 3 Interventional

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
56
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 5:02 PM EST
Recruiting Phase 2 Interventional

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT07333183
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
inhaled mosliciguat, Dry Powder Inhaler
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

NCT03864666
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol 100 mg, PMR 200 mg
Drug
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pimecrolimus Cream for Oral Lichen Planus

NCT00297037
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Pimecrolimus 1% cream
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 3 Interventional Results available

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

NCT00549939
View directory record Official record
Conditions
Neurogenic Urinary Bladder
Interventions
Alfuzosin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 16 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 2 Interventional Results available

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

NCT05869669
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Neflamapimod, Placebo
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
55 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 1, 2026, 5:02 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229
View directory record Official record
Conditions
Alzheimer Disease, Agitation
Interventions
KarXT, KarX-EC
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years to 90 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

NCT03689972
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
52
States / cities
Cullman, Alabama • Homewood, Alabama • Irvine, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Nov 1, 2026, 5:02 PM EST
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

NCT02656303
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ublituximab, Umbralisib
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
69
States / cities
Huntsville, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 1, 2026, 5:02 PM EST
Terminated Phase 2 Interventional Results available

A Study of Soticlestat in Adults and Children With Rare Epilepsies

NCT03635073
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 1, 2026, 5:02 PM EST
Completed Phase 2 Interventional Results available

Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)

NCT00731653
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Combination Product: BCI-024 + BCI-049
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Nov 1, 2026, 5:02 PM EST
Terminated Phase 2Phase 3 Interventional Results available

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

NCT02291237
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Nov 1, 2026, 5:02 PM EST